Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation (2)
Oct 07 2019

Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation (2)

QIAGEN announces CEO leadership transition

Venlo, The Netherlands, October 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces that Peer M. Schatz, Chief Executive Officer, has notified the Company that he has decided to step down as Chief Executive Officer and Chairman of the Management Board. He will remain with QIAGEN as Advisor to the Supervisory Board and transition into this role in the coming weeks. The Supervisory Board will now start a search for a permanent CEO. In the meantime, Thierry Bernard, Senior Vice President, Head of Molecular Diagnostics Business Area, will now act as interim CEO and work in tandem with Roland Sackers, Chief Financial Officer.

 

 

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

ISIN: NL0012169213

Frankfurt Stock Exchange, regulated market (Prime Standard)

 

Contact

John Gilardi

Vice President, Head of Corporate Communications and Investor Relations

+49 2103 29 11711 and +1 240 686 2222

john.gilardi@qiagen.com


FOLLOW US ON SOCIAL MEDIA

Share this page